No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Women with a Genomic Grade Index High-Risk ER-positive, HER2-negative Breast Cancer By Ogkologos - August 19, 2025 187 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ASTER 70s study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Indications for Ibrutinib ESMO Highlights the Importance of Prioritising the Fight Against Cancer in Its Response to the Public Consultation on the EU4Health 2026 Work Programme ESMO Urges EU Policymakers to Protect the Wellbeing of the Oncology Workforce MOST POPULAR Political Interests Are A Major Adversary in the War on Women July 6, 2021 Stage IV Cancer Patient Clinging to Life Overseas While Family Raises... May 28, 2020 Estimate of the Global Economic Cost of the Most Prevalent Cancers... March 13, 2023 Adding Pembrolizumab to Chemotherapy Results in Improved PFS and OS in... November 25, 2024 Load more HOT NEWS ViPOR Regimen Associated with Durable Remissions in Patients with Specific Molecular... Family Brings Joy & Raises Money With Their Extravagant Christmas Light... How to Talk With Your Children About Your Metastatic Cancer Prognosis Καρκίνος Δέρματος
